The world has witnessed a prominent increase in the incidence of blood disorders over the past decade and this has led to a rise in demand for blood disorder treatments. Blood clotting factor concentrates play a crucial role in the treatment of different blood-related disorders and since the incidence of these disorders is on the rise, it is projected to boost demand for coagulation factor concentrates through 2027.
The market for coagulation factor concentrates is set to evolve at a high CAGR of 7.8% over the next five years. Increasing prevalence of Von Willebrand disease and disseminated intravascular coagulation (DIC) disorder is also projected to favor coagulation factor concentrates market growth over the years to come.
Rising adoption of prophylaxis treatment, growing incidence of hemophilia in newborns, upsurge in demand for hemophilia treatment, and high investments in healthcare research and development are other factors that could potentially uplift coagulation factor concentrates market growth over the next five years.
However, the high costs of blood disorder treatments and lack of awareness of blood disorders in developing economies are anticipated to have a hindering effect on the overall coagulation factor concentrates market potential.
Want A Detailed Understanding of Market Functioning? Request for a Sample Here –https://www.factmr.com/connectus/sample?flag=S&rep_id=7677
How Will the Coagulation Factor Concentrates Industry Fare Across Geographies?
“North America & Europe to Spearhead Global Coagulation Factor Concentrates Market Growth”
The North America coagulation factor concentrates market is projected to account for a prominent market share in the global industry landscape throughout the forecast period.
Rapid adoption of novel treatments, the presence of developed healthcare infrastructure, and increasing investments in the healthcare research and development sector are expected to prominently augment coagulation factor concentrate demand in this region through 2027. The market for coagulation factor concentrates in Canada is predicted to evolve at a CAGR of 6.4% over the next five years.
Investments to improve healthcare infrastructure and increasing supportive government initiatives to boost awareness of blood disorders are expected to favor coagulation factor concentrate sales in Europe over the coming years. Key countries that coagulation factor concentrate suppliers should keep an eye out for in this region are France, Italy, Germany, and the United Kingdom.
The Germany coagulation factor concentrates market is anticipated to exhibit expansion at a CAGR of around 4.5% through 2027.
The Asia Pacific coagulation factor concentrates market is anticipated to be driven by an increasing blood-related disorder-affected patient pool and rising investments in healthcare infrastructure development. India is anticipated to be one of the key markets for coagulation factor concentrates owing to the high prevalence of hemophilia in the country.
The coagulation factor concentrates market in China is also expected to be highly opportune owing to the rising focus on healthcare infrastructure development and rising awareness of blood disorders. Demand for coagulation factor concentrates in China is anticipated to rise at a CAGR of 12% over the next five years and hold a value of US$ 2.5 billion by the end of 2027.
What is the Demand Outlook for Coagulation Factor Concentrates in the United States?
“High Research Activity & Rising Availability of Blood Disorder Treatments to Drive U.S. Coagulation Factor Concentrate Sales”
The market for coagulation factor concentrates in the United States is anticipated to be driven by rising investments in the R&D sector and the growing prevalence of blood disorders. High healthcare expenditure and growing adoption of new treatments and therapies are expected to favor the bleeding disorders treatment market and subsequently drive coagulation factor concentrate demand as well.
An increase in government spending to promote research and development activity and initiatives to increase awareness of blood-related disorders are also expected to positively influence coagulation factor concentrates market potential in the U.S.
In 2022, sales of coagulation factor concentrates in the United States account for a revenue value of US$ 2 billion.
Which Type of Coagulation Factor Concentrate Will Exhibit High Demand?
“Coagulation Factor XIII to Lead Market Expansion Going Forward”
The global coagulation factor concentrates market, based on type, is segmented into coagulation factor IX, coagulation factor XIII, and other types.
Demand for coagulation factor XIII is anticipated to be higher than coagulation factor IX owing to its better safety profile and extensive use in the treatment of hemophilia A and hemophilia B diseases. Development of coagulation factor XIII involves virus inactivation similar to plasma-derived coagulation factor concentrates and hence results in a better quality safety profile.
This research on the coagulation factor concentrates industry also provides detailed insights on how demand for coagulation factor IX and other types of coagulation factors is expected to fare over the years to come.
Speak To Research Analyst For Detailed Insights: https://www.factmr.com/connectus/sample?flag=AE&rep_id=7677
Competitive Landscape :
Coagulation factor concentrate providers are focusing on expanding their revenue generation capacity by getting new approval for their products from regulatory authorities.
- In July 2022, Novo Nordisk, a Danish multinational pharmaceutical organization, announced that the United States Food and Drug Administration (FDA) had approved REBINYN®, Coagulation Factor IX, GlycoPEGylated for regular prophylaxis in adults and children. REBINYN is a recombinant DNA-derived coagulation factor IX concentrate.
Other recent developments by key companies such as Baxter International Inc., Octapharma, LFB, Biotest, Green Cross Corporation, Shanghai RAAS Blood Products, and Sanquin have also been listed in this new market study on the coagulation factor concentrates industry.
Key Companies Profiled:
- CSL Behring
- Shire
- Kedrion S.P.A.
- Grifols
- Baxter International Inc.
- Octapharma
- LFB
- Novo Nordisk A/S
- Biotest
- Green Cross Corporation
- Shanghai RAAS Blood Products
- Sanquin
- Bio Product Laboratory
- Medscape
Key Segments in Coagulation Factor Concentrates Industry Research
By Type :
- Coagulation Factor IX
- Coagulation Factor XIII
- Other Types
By End User :
- Hospitals & Clinics
- Research Laboratories
- Academic Institutions
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Interested to Procure The Data? Inquire here at –https://www.factmr.com/checkout/7677
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com